Cargando…

Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients

PURPOSE: Registered trials and real-world evidence (RWE) studies provided evidence on the efficacy of once-weekly (OW) semaglutide on hyperglycaemia and cardiovascular risk factors as add-on or de-novo treatment in type 2 diabetes (T2D). METHODS: In a retrospective analysis of electronic data files...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marzullo, P., Daffara, T., Mele, C., Zavattaro, M., Ferrero, A., Caputo, M., Prodam, F., Aimaretti, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270295/ https://www.ncbi.nlm.nih.gov/pubmed/35429298 http://dx.doi.org/10.1007/s40618-022-01799-2

Ejemplares similares

Gestational Diabetes Mellitus: Clinical Characteristics and Perinatal Outcomes in a Multiethnic Population of North Italy
por: Caputo, M., et al.
Publicado: (2021)

Bone Response to Weight Loss Following Bariatric Surgery
por: Mele, Chiara, et al.
Publicado: (2022)

Neuroinflammation and Hypothalamo-Pituitary Dysfunction: Focus of Traumatic Brain Injury
por: Mele, Chiara, et al.
Publicado: (2021)

Case Report: Liraglutide for Weight Management in Beckwith-Wiedemann Syndromic Obesity
por: Caputo, Marina, et al.
Publicado: (2021)

Immunomodulatory Effects of Vitamin D in Thyroid Diseases
por: Mele, Chiara, et al.
Publicado: (2020)

Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany
por: Menzen, Markus, et al.
Publicado: (2023)

Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01)
por: Berra, Cesare C., et al.
Publicado: (2023)

Beyond bariatric surgery and weight loss medicaments. A systematic review of the current practice in obesity rehabilitative inpatient programs in adults and pediatrics
por: Spadaccini, Daniele, et al.
Publicado: (2022)

Inositols and metabolic disorders: From farm to bedside
por: Caputo, M., et al.
Publicado: (2020)

Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain
por: Garcia de Lucas, Maria Dolores, et al.
Publicado: (2022)

Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study
por: Volpe, Sara, et al.
Publicado: (2022)

Discordant biochemical parameters of acromegaly remission do not influence the prevalence or aggressiveness of metabolic comorbidities: a single-center study
por: Romanisio, Martina, et al.
Publicado: (2023)

Semaglutide once weekly in people with type 2 diabetes: Real‐world analysis of the Canadian LMC diabetes registry (SPARE study)
por: Brown, Ruth E, et al.
Publicado: (2020)

Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study
por: Wolffenbuttel, Bruce H. R., et al.
Publicado: (2022)

Real-World Use of Once-Weekly Semaglutide in Thai Patients With Type 2 Diabetes Mellitus in a Private Hospital Setting
por: Thewjitcharoen, Yotsapon, et al.
Publicado: (2023)

Regulation of GH and GH Signaling by Nutrients
por: Caputo, Marina, et al.
Publicado: (2021)

Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from the SURE UK Multicentre, Prospective, Observational Study
por: Holmes, Patrick, et al.
Publicado: (2021)

Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation
por: Meier, Juris J.
Publicado: (2021)

Circulating adipokines and metabolic setting in differentiated thyroid cancer
por: Mele, Chiara, et al.
Publicado: (2019)

Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial
por: Buse, John B, et al.
Publicado: (2023)

Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study
por: Williams, David M., et al.
Publicado: (2021)

Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1)
por: Wilding, John P H, et al.
Publicado: (2021)

Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide
por: Gallwitz, Baptist, et al.
Publicado: (2021)

Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom
por: Sandhu, Hera, et al.
Publicado: (2023)

Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting
por: Uzoigwe, Chioma, et al.
Publicado: (2021)

Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China
por: Liu, Lei, et al.
Publicado: (2022)

Thyroid function in the subacute phase of traumatic brain injury: a potential predictor of post-traumatic neurological and functional outcomes
por: Mele, C., et al.
Publicado: (2021)

Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups
por: Yale, Jean-François, et al.
Publicado: (2022)

The impact of the metabolic phenotype on thyroid function in obesity
por: Marzullo, Paolo, et al.
Publicado: (2016)

Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study
por: Volpe, Sara, et al.
Publicado: (2022)

A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects
por: Ikushima, Ippei, et al.
Publicado: (2018)

The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark
por: Ehlers, Lars H., et al.
Publicado: (2022)

Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study
por: Lingvay, Ildiko, et al.
Publicado: (2021)

Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression—real-world clinical practice
por: Aviles Bueno, Beatriz, et al.
Publicado: (2022)

Effect of Semaglutide on Subclinical Atherosclerosis and Cardiometabolic Compensation: A Real-World Study in Patients with Type 2 Diabetes
por: Patti, Angelo Maria, et al.
Publicado: (2023)

Real-World Retrospective Study into the Effects of Oral Semaglutide (As a Switchover or Add-On Therapy) in Type 2 Diabetes
por: Candido, Riccardo, et al.
Publicado: (2023)

Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
por: Johansen, Pierre, et al.
Publicado: (2019)

Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program
por: Perreault, Leigh, et al.
Publicado: (2022)

Efficacy and Safety of Subcutaneous and Oral Semaglutide Administration in Patients With Type 2 Diabetes: A Meta-Analysis
por: Zhong, Ping, et al.
Publicado: (2021)

Efficacy and tolerability of the Subcutaneous Semaglutide for type 2 Diabetes patients: an updated systematic review and meta-analysis
por: Hu, Shanshan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5iigep5ro833g50nuv1kegk2c0